Our mission is to develop disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases to address the unmet medical need.
-
Highlight
Topline Phase 1b data webcast
-
Highlight
Herantis Pharma Plc Half Year Report January 1 – June 30, 2025
-
Highlight
H1/2025 Report webcast
-
Highlight
Edison TV interview with Herantis CEO, Antti Vuolanto